Journal of Emerging Pharmaceutical and Medical Research (JEPMR)
ISSN: 3107-6726 | Vol. 02, Issue-02, May-Aug. 2026 | pp. 119-135

Ribose-5-Phosphate Isomerase Deficiency (RPI): AI-Driven Drug Discovery, 3D-Bioprinted Neural Models, Bedrock for Synthesizing RNA, DNA, ATP, BBB and Gene Therapy, Leukoencephalopathy

Vivek Kumar[1], Yash Srivastav[2*], Anup Kumar Sirbaiya[1], Shivani Singh[2]

[1]K.P. Singh Memorial Institute of Pharmacy, Sitapur, U.P, India. 261207
[2]D.K.R.R Pharmacy College, Amberpur, Sitapur, Uttar Pradesh, India

***Corresponding Author E-mail: yashsrv.108@gmail.com**

Abstract
Ribose-5-Phosphate Isomerase Deficiency (RPI deficiency) is an ultra-rare genetic neurometabolic condition characterized by mutations in the RPIA gene, which causes disruptions in the non-oxidative pentose phosphate pathway. Disturbances in the metabolism of ribose-5-phosphate lead to disturbances in RNA, DNA, ATP, and other nucleotides' production, causing oxidative stress, mitochondrial defects, and neurological symptoms, such as leukoencephalopathy. This review outlines the molecular genetics, biochemistry, pathogenesis, and symptoms of RPI deficiency, and emphasizes the involvement of ribose-5-phosphate in the nucleotide and energy production within cells. Recent advancements in artificial intelligence (AI)-based drug discovery, precision medicine, metabolic pathway simulation, and drug repositioning for the identification of new drug targets are highlighted. Next-generation technologies including three-dimensional (3D) printed neural models, organoids derived from patient tissues, digital twins, drugs targeted against blood-brain barrier, and gene therapy are also described due to their capability to provide additional benefits for disease modeling and personalized medicine. At last, possible issues and future perspectives regarding the application of this technology to the clinic are presented in this review. The combination of AI, multi-omics tools, and new human-based disease models is expected to be a very promising approach for drug discovery and disease management of Ribose-5-Phosphate Isomerase Deficiency.

Keywords: Ribose-5-Phosphate Isomerase Deficiency; Pentose Phosphate Pathway; Artificial Intelligence (AI); Precision Medicine; Gene Therapy; 3D Bioprinting; Brain Organoids; Leukoencephalopathy.

Received: May 11, 2026 **Revised: June 01, 2026** **Accepted: July 22, 2026** **Published: Aug. 07, 2026**

DOI: https://doi.org/10.64474/3107-6726.Vol2.Issue2.7

https://jepmr.nknpub.com/1/issue/archive

1. INTRODUCTION

RPI deficiency is an extremely rare genetic neurometabolic disease associated with the presence of mutations in the RPIA gene, responsible for producing ribose-5-phosphate

isomerase, an enzyme involved in the non-oxidative part of the PPP cycle[1]. This enzyme plays a pivotal role in converting ribose-5-phosphate and ribulose-5-phosphate, contributing to nucleotide production and metabolism of cells. As there is no more than a few cases of the disease in the world, the disease has gained increased scientific attention due to its serious neurologic symptoms, including leukoencephalopathy, developmental delay, seizures, cerebellar atrophy, and cognitive impairment[2].

Advancements in areas such as AI, computational biology, multi-omics techniques, gene-editing systems, and human models of diseases have revolutionized rare disease research. AI-enabled drug discovery, metabolomics, bioprinting of 3D neural tissues, organoids derived from patients, digital twins, and precision medicine techniques are some of the ways through which disease mechanisms can be understood and therapeutics can be discovered and developed. Moreover, the development of blood-brain barrier (BBB) transporters and gene therapy are some of the advancements that can be exploited in order to surmount the challenges faced by existing therapeutics. Overall, these advancements provide a robust foundation for the development of personalized treatment strategies for Ribose-5-Phosphate Isomerase Deficiency[3].

1.1 Background and Context

Ribose-5-Phosphate Isomerase is a key enzyme responsible for balancing carbohydrate and nucleotide metabolism via the pentose phosphate pathway. Any abnormality in the enzyme's activity would result in deficiency of ribose sugars necessary for the synthesis of RNA, DNA, ATP, NAD, and other cofactors synthesized from nucleotides necessary for cell proliferation, DNA damage repair, nerve functions, and energy metabolism. As neurons have particularly high metabolic requirements, abnormalities in RPI activity mostly affect the central nervous system leading to neurodegeneration. Although substantial advances have been made in molecular genetics and metabolomics, insufficient data have been accumulated to understand the disease mechanisms fully and develop effective therapies[4].

1.2 Objectives of the Review

The primary objectives of this review are:

- To cover the molecular mechanism and biochemical aspects of Ribose-5-Phosphate Isomerase deficiency.
- To explain the role of RPI in RNA, DNA, and ATP synthesis.
- To describe the neurological features and pathogenesis of the disease.
- To cover AI-assisted drug discovery and precision medicine concepts.
- To cover emerging human-based disease models and gene therapy approaches.
- To cover current challenges and future perspectives in treatment.

1.3 Importance of the Topic

Relevance of RPI deficiency goes beyond its rarity due to the fact that this condition offers important insight regarding the interaction between nucleotide metabolism, energy balance, and neural functions. The development of artificial intelligence, precision medicine, and biotechnology has provided an unprecedented opportunity for the study of the mechanisms involved in the disease and the creation of personalized approaches that could not be developed before[5]. Thus, a systematic analysis combining molecular biology, drug discovery using artificial intelligence, 3D-bioprinted neural tissues, targeted treatment of blood-brain barrier, and gene editing approaches is warranted and necessary.

2. AI-DRIVEN DRUG DISCOVERY AND EMERGING THERAPEUTIC TECHNOLOGIES

The recent advancements in AI, systems biology, and bioengineering are changing the approaches towards the investigation of rare genetic diseases, among which RPI can be highlighted. Due to the extreme rarity of RPI deficiency and scarcity of patients with this condition, traditional methods of pharmacological research and investigation of the disease are restricted by lack of biological information and absence of disease-specific models. The use of AI-enabled computational approaches, multi-omics analysis, and more advanced human experimental systems allow researchers to reveal mechanisms of the disease, identify potential targets, predict the efficiency of the drugs, and speed up translational research. Simultaneously, 3D-bioprinted neural tissues, organoids, and digital twin techniques represent innovative and biologically relevant platforms for studying the pathogenesis of the disease and implementing personalized approaches to treatment[6].

2.1 AI-Based Drug Discovery and Target Identification

In the drug discovery process, AI is an important tool that incorporates genomics, proteomics, metabolomics, structural biology, and biomedical literature to discover new drug targets. In the case of rare metabolic diseases like Ribose-5-Phosphate Isomerase Deficiency, AI algorithms can quickly scan through biological data sets and pinpoint disrupted metabolic pathways due to the RPIA mutation. AI approaches such as machine learning, deep learning, and computational network-based approaches allow scientists to make predictions of enzyme malfunctioning and compensatory metabolic pathways and molecules to restore the pentose phosphate pathway. The computational tool greatly saves time and money as opposed to conventional drug discovery techniques[7].

Moreover, the AI system enables virtual screening of hundreds of thousands of chemicals on the 3D structure of ribose-5-phosphate isomerase, which helps quickly find chemicals with good binding properties and pharmacodynamics. The structure-based design of drugs, molecular docking, molecular dynamics modeling, and quantitative structure-activity

relationship (QSAR) models assist in optimizing the lead compounds before experimental validation. Additionally, drug repositioning platforms powered by AI can discover drugs that have already been approved and could be useful in stabilizing the mutant enzyme of RPI, improving nucleotide metabolism, and reducing oxidative stress.

Another key benefit of AI is the capacity of such systems to combine various clinical data coming from genomics sequencing, metabolomics analysis, neuroimaging, EHRs, and patient registries. Algorithms that employ explainable AI can help find disease biomarkers that are responsible for disease progression and predict patient's responsiveness to therapy. Moreover, they can classify patients according to their molecular profile[8]. This approach allows for designing personalized treatment plans and helps in discovering new therapy targets that can positively affect neurological outcome in patients with RPI deficiency.

2.2 AI-Assisted Precision Medicine and Metabolic Pathway Modeling

Precision medicine is an attempt to deliver personalized therapies to patients based on their unique genetic, molecular, and clinical properties[9]. For RPI deficiency, the use of AI involves genomics sequencing, transcriptomics, metabolomics, and phenotypes to develop complete models of diseases showing how RPIA mutations affect cellular metabolism. These computational models allow clinicians to understand the disease heterogeneity, predict the severity of the condition, and develop patient-specific treatment plans.

Metabolic pathway simulation using AI technology has been especially useful in examining metabolic disturbances in the pentose phosphate pathway. Metabolic fluxes, enzyme kinetics, nucleotide synthesis, redox balance, and ATP generation can be studied under various physiological circumstances through computational analysis. These simulations determine metabolic limitations caused by the RPI defect and how treatments such as pharmacological approaches, nutritional supplementation, enzyme replacement, and gene therapy can correct biochemical processes[10]. The incorporation of whole-genome metabolic network models provides insight into metabolic relationships between carbohydrate metabolism, mitochondrial functions, oxidative stress, and neuron survival.

Apart from diagnosis and pathway analysis, AI is useful for ongoing therapy optimization via predictive analytics and patient monitoring. Using machine learning algorithms, it is possible to analyze repeated lab results, magnetic resonance imaging, neurological examination, and biochemical biomarkers to predict the course of the disease and assess the effectiveness of treatment[11]. This helps to optimize therapy timing and modify the interventions based on disease progression and reduce the side effects. Therefore, precision medicine with the help of AI is a good solution to manage RPI deficiency[12].

2.3 3D-Bioprinted Neural Models, Organoids, Digital Twins and Human-Based Disease Models

The emergence of innovative human-based models for disease studies has been of great benefit to the research on RPI deficiency. In contrast to the traditional culture of cells and animals used as disease models, innovative technologies like 3D bioprinting, human organoids, digital twins, and iPSC models are capable of creating an exact human condition both neurologically and metabolically[13]. This is achieved by combining the above methods with the use of AI technology.



Figure 1. AI-integrated organoid platform for disease modeling, high-throughput drug screening, and precision medicine.

- **3D-Bioprinted Neural Models:** The 3D bioprinted neural models resemble very closely the structural and functional properties of brain tissue from humans for testing neuronal disorders, oxidative stress, mitochondrial disorders, and white matter degeneration associated with the RPI deficiency. The models are also used for AI-supported drug screening.
- **Patient-Derived Brain Organoids:** Patient derived brain organoids using iPSCs maintain the specific mutations found in RPIA, facilitating research on disease pathogenesis and genotype/phenotype correlations[14]. With the use of CRISPR gene editing and AI technology, they can be effectively utilized to test personalized therapies.
- **Digital Twin Technology:** Digital twins use computerized patient models that use genomic, metabolomic, neuroimaging, and clinical data. AI makes use of these computerized models to predict disease progression, simulate treatment and optimize therapy.
- **Human-Based Disease Models:** The human disease models that include iPSCs, organ on chips and ex vivo neurons faithfully recapitulate the molecular pathology of RPI

deficiency. Such technologies facilitate biomarker identification, drug discovery, and AI-enabled precision medicine[15].

3. MOLECULAR BIOLOGY, PATHOGENESIS AND THERAPEUTIC ADVANCES

RPI deficiency is considered the least common inherited disease related to the non-oxidative part of the pentose phosphate pathway (PPP). It arises due to mutations in the RPIA gene and affects the conversion between ribose-5-phosphate and ribulose-5-phosphate, which leads to disturbances in the synthesis of nucleotides, energy metabolism, and redox reactions[16]. Despite the scarcity of known cases of RPI deficiency, the disease is associated with significant neurological problems such as progressive leukoencephalopathy, developmental disorders, epilepsy, and white matter damage. This information highlights the importance of the RPI enzyme in normal brain development. With recent achievements in molecular genetics, metabolomics, neuroimaging, BBB research, and gene therapy, our knowledge about the pathogenesis of this disease has increased significantly.

3.1 Ribose-5-Phosphate Isomerase Deficiency: Genetics and Biochemistry

The RPI deficiency is a genetic autosomal recessive condition, where the RPIA gene, encoding ribose-5-phosphate isomerase (RPI) – one of the most crucial enzymes in the non-oxidative part of the pentose phosphate pathway, is altered. This enzyme is responsible for the reversible transformation of ribose-5-phosphate (R5P) to ribulose-5-phosphate (Ru5P)[17]. It maintains the balance between the metabolism of carbohydrates and the synthesis of nucleotides, and mutations leading to decreased enzyme function cause an imbalance and the accumulation of metabolites and failure of nucleotides' synthesis.

Bimolecularly, the role of the pentose phosphate pathway includes two main functions which include formation of NADPH for antioxidant activity and production of ribose for nucleotide biosynthesis[18]. Even though the role of RPI is mainly involved in the non-oxidative pathway, problems associated with the enzyme can affect different interconnected metabolic pathways which include glycolysis, purine pathway, pyrimidine pathway, and mitochondrial energy metabolism. This decreases metabolic flexibility, causes oxidative stress, impairs DNA repair mechanism, and affects cell proliferation especially in the metabolically active tissue like the CNS[19].

The molecular effects associated with RPIA mutations depend on the nature of the mutation and its exact location. While missense mutations can affect enzyme efficiency or the stability of protein structure, splice-site and nonsense mutations can result in a significant reduction in functional enzyme levels[20]. With the help of whole-exome sequencing, whole-genome sequencing, metabolomics, and bioinformatics, it has become easier to detect pathogenic variants. AI-powered prediction of protein structure and molecular dynamics analysis enable the analysis of the effects of specific mutations.

3.2 Role of RPI in RNA, DNA and ATP Biosynthesis

The pentose phosphate pathway generates ribose-5-phosphate, which acts as a precursor for many biosynthetic and metabolic reactions. Through the enzymatic action of ribose-5-phosphate isomerase (RPI), sufficient amounts of ribose sugar are ensured to carry out nucleotide synthesis and other biochemical activities. Thus, absence of RPI leads to the disruption of various biochemical pathways, especially in rapidly growing and metabolizing tissues like the brains.



Figure 2. Central role of ribose-5-phosphate in the pentose phosphate pathway and its contribution to nucleotide biosynthesis, redox homeostasis, and cellular metabolism.

- **RNA Biosynthesis:** This compound supplies the ribose sugar that is needed for the synthesis of ribonucleotides, the components from which RNA is built. Sufficient production of RNA is necessary for gene expression, protein synthesis, cell differentiation, and normal neurodevelopment[21].
- **DNA Biosynthesis:** RPI contributes to DNA biosynthesis through providing ribose-5-phosphate for the biosynthesis of purine and pyrimidine nucleotides. Limitation of nucleotides makes DNA replication, DNA repair, and cell division difficult. Therefore, cells become more susceptible to mutations.
- **ATP Production:** The ATP molecule has a ribose molecule whose source is ribose-5-phosphate metabolism. Lack of RPI results in reduced ATP, leading to compromised neuronal metabolism, synapse functioning, ion transport, and cellular function[22].
- **Purine and Pyrimidine Metabolism:** Ribose-5-phosphate is an essential component in the biosynthesis of purines and pyrimidines. Disturbance in the biosynthesis of these compounds impacts nucleotide metabolism, cell growth, and tissue homeostasis in the body.

- **Synthesis of Nucleotide Cofactors:** RPI is involved in the biosynthesis of cofactors made from nucleotides, such as NAD, NADP, FAD, and coenzyme A, and these take part in many enzymatic processes. A deficiency in RPI may affect redox control and oxidative metabolism.
- **Cellular Growth and Proliferation:** Nucleotide synthesis must continue in order to ensure healthy cell growth, tissue repair, and embryonic development[23]. The lower availability of ribose-5-phosphate affects nucleic acid synthesis, thereby slowing down the process of cell multiplication.
- **Neuronal Development and Function:** The neurons require extremely high metabolism and thus, constant production of nucleotides and ATP. Hence, deficiency of RPI leads to improper development of neurons, degeneration of the white matter, and subsequent neurological dysfunctions.
- **Maintenance of Metabolic Homeostasis:** Maintenance of metabolic homeostasis is achieved through regulation of carbon flow in the pentose phosphate pathway that is non-oxidative. Lack of RPI causes disruption of metabolic pathways that results in oxidative stress and mitochondrial dysfunction.
- **Potential Therapeutic Target:** Knowing the metabolic functions of RPI helped to develop AI-powered metabolic pathway models to find out ways to compensate and treat the problem. There are many different uses of such technologies as drug repurposing, stabilization of enzymes, metabolic supplementation, and precision medicine.

3.3 Neurological Manifestations, White Matter Disease and Leukoencephalopathy

The brain is the most commonly affected organ in RPI deficiency since nerve tissue needs constant production of nucleotides, proper mitochondrial activity, and oxidation balance control. Patients usually develop progressive neurodevelopmental delay, epilepsy, cerebellar ataxia, spasticity, optic neuropathy, mental retardation, and regression. The extent of the involvement of the nervous system corresponds to the susceptibility of neurons and oligodendrocytes to changes in nucleotide metabolism and energy production.

Another hallmark pathological feature that can be seen in patients with RPI deficiency is progressive leukoencephalopathy due to severe degeneration of the cerebral white matter. In magnetic resonance imaging (MRI), diffuse white matter pathology, cerebellar atrophy, increased size of ventricles, and pathological alterations of various brain regions can usually be seen. The degeneration of the white matter is presumed to occur due to myelin degeneration, mitochondria dysfunction, oxidative stress, axon disintegration, and decreased number of nucleotides necessary for the oligodendrocytes[24].

Innovations in the fields of neuroimaging, quantitative MRI, diffusion tensor imaging, metabolomics, and computer-aided image interpretation have greatly enhanced the ability to characterize neurological alterations associated with rare metabolic diseases. Machine learning tools are capable of detecting minute imaging biomarkers, evaluating the progression of the disease, and establishing associations between structural alterations and specific gene mutations and clinical outcomes. These approaches help in diagnosing the disease at an early stage, monitoring its progression, and assessing treatment effectiveness.

3.4 Blood-Brain Barrier, Gene Therapy and Future Precision Medicine

The BBB represents one of the major hurdles that have to be overcome in order to develop efficient drugs for the treatment of RPI deficiency since it hampers the transport of many pharmaceutical drugs into the brain[25]. The BBB acts as a selective interface that prevents the entry of toxic compounds while at the same time blocking the passage of drugs, enzymes, nucleic acids, and biologicals into the brain.

Gene therapy is considered to be one of the most promising strategies for addressing the molecular pathology in RPI deficiency. Gene vectors, including the use of adeno-associated virus (AAV) carriers, delivery system using lipid nanoparticles, mRNA therapy, and CRISPR-Cas genome editing systems are studied to find out their effectiveness in restoring the normal function of the RPIA enzyme. Patient's induced pluripotent stem cells, brain organoids and AI modeling allow testing the vector efficiency and treatment safety prior to using it in practice.

In future, the precision medicine approaches would incorporate genomic sequencing, metabolomics, proteomics, neuroimaging, digital twins, and AI to develop patient specific therapeutic modalities[26]. AI can predict disease progression, optimize the delivery methods for genes, personalize treatments, and predict the individuals who can benefit the most from the targeted therapies. This combination of nanotechnology that targets the BBB, gene editing, multi-omics, and AI holds great promise in terms of the diagnosis and treatment of Ribose-5-Phosphate Isomerase Deficiency.

Table 1. Molecular characteristics, pathological mechanisms, and emerging therapeutic strategies for Ribose-5-Phosphate Isomerase Deficiency

Aspect	**Key Features**	**Clinical/Therapeutic Significance**
Genetics	Autosomal recessive mutations in **RPIA**	Cause reduced or absent RPI enzyme activity
Biochemistry	Defective conversion of ribose-5-phosphate and ribulose-5-phosphate	Disrupts pentose phosphate pathway and nucleotide metabolism

Molecular Consequences	Impaired RNA, DNA, ATP, NAD, and nucleotide synthesis	Leads to oxidative stress and mitochondrial dysfunction
Neurological Pathology	Progressive leukoencephalopathy, white matter degeneration, epilepsy, developmental delay	Major determinant of disease severity
Blood-Brain Barrier	Restricts therapeutic delivery to the central nervous system	Necessitates BBB-targeted drug and gene delivery systems
Emerging Therapies	AI-driven drug discovery, metabolic pathway modeling, CRISPR gene editing, AAV-mediated gene therapy, 3D-bioprinted neural models	Supports precision medicine and future personalized treatment approaches

4. TRANSLATIONAL RESEARCH, CLINICAL ADVANCES AND FUTURE THERAPIES

However, translation of scientific advancements into practical treatments is still among the biggest issues facing RPI. The rarity of the condition has made it difficult for scientists to come up with a standardized treatment regime due to insufficient patient sample size and lack of knowledge on the condition's molecular pathophysiology. Thankfully, modern developments in areas like translational medicine, AI, multi-omics studies, genome editing, and precision medicine have enabled quick discoveries into both the mechanisms behind the disease and possible ways of treatment[27]. It appears that the link between lab-based studies and practical implementation in medicine is finally being built.

4.1 Human Disease Models and Clinical Translation

The disease models for human diseases have emerged as key tools to explore the pathophysiology of RPI deficiency and assess any potential therapeutic intervention before applying it in the clinical setting. The models such as iPSCs derived from patients, brain organoids, neural spheroids, organ-on-chip technologies, and neural cultures in vitro have been found to mimic the genetics and biochemistry of affected individuals. The models are useful in studying the neuronal impairment, nucleotide metabolism dysfunction, oxidative stress, mitochondrial dysfunction, and white matter degeneration caused by RPI deficiency.

Whereas traditional animal models provide genetically heterogeneous individuals, human-derived experimental models retain the specific genetic background of the patients and reflect heterogeneity of diseases more accurately. This helps researchers to examine genotype-phenotype relationships, validate molecular targets, and assess the effectiveness and safety of potential drug candidates in laboratory settings. Combining CRISPR technology for gene

editing with human-derived organoids helps researchers to directly assess mutation repair and restoration of proper cell functioning.

Clinical translation needs to be validated comprehensively with biomarker discovery, pharmacokinetics, safety studies, and patient monitoring longitudinally. Neuroimaging, metabolomics, AI-driven biomarker discovery, and clinical registry databases have been contributing to the objective evaluation of diagnostics and treatment results. With increasing international collaborations and patient databases, these translational platforms are likely to fast-track the development of evidence-based treatments for RPI deficiency.

4.2 AI, Multi-omics, Gene Editing and Drug Repurposing

The advent of AI has revolutionized the field of precision medicine through the application of genomic, transcriptomic, proteomic, metabolomic, and clinical data in the creation of disease-oriented computational models. Through AI-based algorithms, it is possible to establish dysregulated pathways in diseases, predict the progression of the disease, develop novel diagnostic biomarkers, and target genes that result from RPIA mutation. Machine learning models allow for predictions on treatment response and personalized medicine decision-making[28].

The use of multi-omics approaches to get a comprehensive understanding of the pathology of the disease is achieved through integrating data derived from genomics, transcriptomics, proteomics, metabolomics, and epigenomics. Data generated through multi-omics approaches uncover molecular interactions that are involved in neuronal dysfunction and metabolism during RPI deficiency. At the same time, genome editing techniques such as CRISPR Cas, AAV vectors, mRNA therapies, and lipid nanoparticles are promising treatment strategies for correcting RPIA mutations.

Moreover, the role of AI in facilitating drug repurposing through testing thousands of pharmaceutical substances against disease-specific molecular targets has been greatly enhanced. Various computational methods including computational docking, network pharmacology, and virtual screening have enabled faster identification of the appropriate drugs which could be used to stabilize mutant enzymes of RPI, mitigate oxidative stress, improve mitochondrial activity, or increase nucleotide metabolism.

4.3 Challenges, Ethics and Future Clinical Implementation

Though tremendous advances have been made in science, there remain certain hurdles that stand in the way of the efficient translation of therapeutic modalities for RPI deficiency. These obstacles include the exceptionally small number of documented cases, insufficient natural history data, wide-ranging phenotypic variability, and the challenge associated with administering treatment across the blood-brain barrier. Besides, while AI is proving to hold immense promise for diagnostics and pharmacology, predictive models largely need to be validated through larger patient cohorts before being put into practice.

❖ Challenges in Clinical Translation

The scarcity of patients with RPI deficiency hinders larger clinical trials, thus making it difficult to develop evidence on the effectiveness of treatment and long-term outcome. Besides, poor understanding of the disease process, lack of biomarkers for RPI deficiency, and technical problems related to BBB-based drug delivery remain stumbling blocks towards developing effective therapies[29].

❖ Ethical Considerations

The use of genome sequencing, artificial intelligence-enabled decision support, and gene-editing technologies presents various ethical challenges ranging from issues of patient privacy, informed consent, data security, transparency of algorithms, to accessibility to advanced treatment options. Gene editing technologies like CRISPR-Cas systems also need to be evaluated from the perspective of safety, off-target gene alterations, and regulation.

❖ Future Clinical Implementation

Future treatments will be a combination of artificial intelligence-based precision medicine, multi-omics data, digital twin techniques, brain barrier targeting drug delivery system, gene therapy for individual patients and continuous patient monitoring using a holistic approach. International patient databases, research collaborations, diagnosis protocols, and adaptive clinical trials will play a vital role in developing precision therapy for Ribose-5-Phosphate Isomerase Deficiency.

Table 2. Selected Studies Supporting RPI Deficiency Research and Therapeutic Advances

Author(s) & Year	Study Focus	Major Finding	Significance
Nieh et al. (2022)[30]	RPIA suppression	RPIA inhibition induces ROS, autophagy, apoptosis, and senescence.	Demonstrates the critical role of RPIA in cellular metabolism.
Qiao et al. (2025)[31]	Pentose phosphate pathway	PPP regulates nucleotide synthesis, redox balance, and metabolism.	Supports the metabolic basis of RPI deficiency.
Qiu et al. (2015)[32]	miRNA regulation of RPIA	miR-124 suppresses RPIA and reduces nucleotide synthesis.	Highlights molecular regulation of RPIA as a therapeutic target.

Rashida & Laxman (2021)[33]	PPP metabolic network	PPP coordinates cellular growth and metabolic homeostasis.	Explains the biochemical importance of RPI in normal physiology.
Serrano et al. (2024)[34]	AI in drug discovery	AI improves target identification, drug repurposing, and personalized therapy.	Supports AI-based therapeutic strategies for RPI deficiency.

5. DISCUSSION

RPI deficiency is an extremely rare genetic disorder of the pentose phosphate pathway characterized by a very small number of documented cases. Despite the disease being rare, the recent progress in molecular genetics, metabolomics, artificial intelligence, human disease modeling and precision medicine greatly contributes to accumulating knowledge about its molecular pathology and treatment[35]. This review presents a thorough analysis of existing data concerning the disease etiology, neurologic complications, AI-assisted drug design, novel approaches in therapy, and translational medicine. The main results, their clinical importance, current limitations in scientific studies and further perspectives of creating personalized therapies for RPI deficiency are discussed below.

5.1 Interpretation and Analysis of Findings

The existing literature shows that RPI deficiency is a complicated neurometabolic disease caused by the disturbance in the non-oxidative pentose phosphate pathway, which results in problems with nucleotide synthesis, oxidative stress, mitochondrial dysfunction, and the development of neurological symptoms. The latest progress in molecular genetics, metabolomics, and neuroimaging has led to a greater understanding of the disease pathogenesis, while AI has facilitated the process of target discovery, analysis of metabolic pathways, and drug repositioning. Moreover, new technologies like 3D bioprinting of neural cells, patient-derived organoids, digital twins, and gene editing tools offer an opportunity to study the disease processes in physiologically relevant models and assess potential therapies[36].

5.2 Implications and Significance

This review demonstrates the increasing relevance of combining molecular biology with innovative computational techniques in order to enhance the diagnosis and treatment of ultra-rare metabolic diseases[37]. AI-based precision medicine along with multi-omics approaches and human-specific disease models creates possibilities for early diagnosis, individualized treatment, and drug discovery. In addition, developments in the field of drug delivery across the BBB and gene therapy create promising directions for overcoming current challenges, focusing on the potential of an interdisciplinary approach for clinical practice in Ribose-5-Phosphate Isomerase Deficiency[38].

5.3 Research Gaps and Limitations

However, there are still many restrictions preventing the development of new therapies for RPI deficiency despite all the achievements in the field. First of all, the extremely small number of patients described in literature, absence of long-term clinical information, lack of standardized biomarkers, and no multicenter clinical studies limit the ability to understand the course of the disease and effectiveness of the therapy[39]. Furthermore, some models of gene editing and AI-predicted therapy models are at the preclinical stage yet.

5.4 Future Research Directions

Future research efforts must be directed towards broadening patient registry internationally, designing diagnostic markers, and applying genomics, metabolomics, proteomics, and neuroimaging techniques to precision medicine approach. Progress in drug discovery using AI technology, digital twin technology, drugs that target blood-brain barrier, gene editing with CRISPR technology, and use of patient-derived organoids will further hasten the process. Collaborative multidisciplinary research involving computational biology, biotechnology, and medicine will certainly help translate the novel therapies to personalized therapies for Ribose-5-Phosphate Isomerase Deficiency[40].

6. CONCLUSION

RPI deficiency is among the rarest inherited metabolic diseases, which is associated with a disruption of the pentose phosphate pathway and progressive neurological deficits due to impaired nucleotide synthesis. Despite the lack of any disease-specific treatment approaches, there have been many developments in the field of molecular biology, artificial intelligence, omics science, human disease modeling, BBB drug delivery systems, and gene therapy that helped increase knowledge about the disease and its treatment opportunities. Combining AI drug discovery, precision medicine, 3D bioprinting of neural models, digital twin technology, and genome editing can become an important trend in the future research. International cooperation, clinical research, and translational studies will be crucial for development of new safe, efficient and personalized treatment approaches for RPI deficiency patients.

REFERENCES

1. Abbas, S. R., Abbas, Z., Zahir, A., & Lee, S. W. (2025). Advancing genome-based precision medicine: A review on machine learning applications for rare genetic disorders. Briefings in Bioinformatics, 26(4), bbaf329.
2. Abdallah, S., Sharifa, M., Almadhoun, M. K. I. K., Khawar Sr, M. M., Shaikh, U., Balabel, K. M., ... & Kanwar Sr, M. (2023). The impact of artificial intelligence on optimizing diagnosis and treatment plans for rare genetic disorders. Cureus, 15(10).

3. Banfalvi, G. (2021). Prebiotic pathway from ribose to RNA formation. International journal of molecular sciences, 22(8), 3857.
4. Bhattacharjee, P., Wang, D., Anderson, D., Buckler, J. N., de Geus, E., Yan, F., ... & Sadler, A. J. (2024). The immune response to RNA suppresses nucleic acid synthesis by limiting ribose 5-phosphate. The EMBO journal, 43(13), 2636.
5. Bombieri, C., Corsi, A., Trabetti, E., Ruggiero, A., Marchetto, G., Vattemi, G., ... & Romanelli, M. G. (2024). Advanced cellular models for rare disease study: exploring neural, muscle and skeletal organoids. International journal of molecular sciences, 25(2), 1014.
6. Brasil, S., Pascoal, C., Francisco, R., dos Reis Ferreira, V., A. Videira, P., & Valadão, G. (2019). Artificial intelligence (AI) in rare diseases: is the future brighter?. Genes, 10(12), 978.
7. Brooks, S. S., Anderson, S., Bhise, V., & Botti, C. (2018). Further delineation of ribose-5-phosphate isomerase deficiency: report of a third case. Journal of child neurology, 33(12), 784-787.
8. Chen, J., Wu, H., Zhang, W., & Mu, W. (2020). Ribose-5-phosphate isomerases: characteristics, structural features, and applications. Applied microbiology and biotechnology, 104(15), 6429-6441.
9. Chou, Y. T., Jiang, J. K., Yang, M. H., Lu, J. W., Lin, H. K., Wang, H. D., & Yuh, C. H. (2018). Identification of a noncanonical function for ribose-5-phosphate isomerase A promotes colorectal cancer formation by stabilizing and activating β-catenin via a novel C-terminal domain. PLoS Biology, 16(1), e2003714.
10. Cossu, V., Bonanomi, M., Bauckneht, M., Ravera, S., Righi, N., Miceli, A., ... & Marini, C. (2020). Two high-rate pentose-phosphate pathways in cancer cells. Scientific reports, 10(1), 22111.
11. Elhassan, S., & Mojadidi, S. (2025, April). Fifth Known Case of the Second Rarest Disease: Ribose 5-phosphate Isomerase Deficiency (P7-3.001). In Neurology (Vol. 104, No. 7_Supplement_1, p. 1984). Hagerstown, MD: Lippincott Williams & Wilkins.
12. Fang, X., & Xu, G. (2025). The energy metabolic function and biosynthetic role of the pentose phosphate pathway. Journal of Energy Bioscience, 16.
13. Foksinska, A., Crowder, C. M., Crouse, A. B., Henrikson, J., Byrd, W. E., Rosenblatt, G., ... & Might, M. (2022). The precision medicine process for treating rare disease using the artificial intelligence tool mediKanren. Frontiers in Artificial Intelligence, 5, 910216.
14. Gangwal, A., & Lavecchia, A. (2024). AI-driven drug discovery for rare diseases. Journal of Chemical Information and Modeling, 65(5), 2214-2231.
15. Ghanem, N., El-Baba, C., Araji, K., El-Khoury, R., Usta, J., & Darwiche, N. (2021). The pentose phosphate pathway in cancer: regulation and therapeutic opportunities. Chemotherapy, 66(5-6), 179-191.

16. Gopi, B., & Felic, S. (2024). Ribose-5-Phosphate Isomerase: A Critical Enzyme in Cellular Metabolism and Therapeutic Target in Disease. medtigo Journal of Medicine, 2(4).

17. He, D., Wang, R., Xu, Z., Wang, J., Song, P., Wang, H., & Su, J. (2024). The use of artificial intelligence in the treatment of rare diseases: a scoping review. Intractable & Rare Diseases Research, 13(1), 12-22.

18. Jayasundara, A., & Abeysekera, N. (2023). Exploring the role of the pentose phosphate pathway in macrophage function. PEXACY International Journal of Pharmaceutical Science, 2(12), 262-275.

19. Jin, L., & Zhou, Y. (2019). Crucial role of the pentose phosphate pathway in malignant tumors. Oncology letters, 17(5), 4213-4221.

20. Karad, V., Patil, P., & Gupta, G. L. (2025). 3D Bioprinting Neural Models: A New Era in Drug Discovery and Neuropharmacology. Biomedical Materials & Devices, 1-22.

21. Kaur, P., Wamelink, M. M., van der Knaap, M. S., Girisha, K. M., & Shukla, A. (2019). Confirmation of a Rare Genetic Leukoencephalopathy due to a Novel Bi-allelic Variant in RPIA. European journal of medical genetics, 62(8), 103708.

22. Khalifa, F. K. (2015). Regulation of gluconeogenesis and pentose phosphate pathway by intracellular and external metabolic regulators: A review. European Journal of Biochemistry, 2(5), 206-213.

23. LeClair, R. J. (2021). Pentose Phosphate Pathway (PPP), Purine and Pyrimidine Metabolism. Cell Biology, Genetics, and Biochemistry for Pre-Clinical Students.

24. Loopmans, S., Rohlenova, K., van Brussel, T., Stockmans, I., Moermans, K., Peredo, N., ... & Carmeliet, G. (2025). The pentose phosphate pathway controls oxidative protein folding and prevents ferroptosis in chondrocytes. Nature Metabolism, 7(1), 182-195.

25. Louit, A., Galbraith, T., & Berthod, F. (2023). In vitro 3D modeling of neurodegenerative diseases. Bioengineering, 10(1), 93.

26. Lovett, M. L., Nieland, T. J., Dingle, Y. T. L., & Kaplan, D. L. (2020). Innovations in 3D tissue models of human brain physiology and diseases. Advanced functional materials, 30(44), 1909146.

27. Maner, S. S., Jadhav, P. P., Kamble, D. D., Hande, A. V., & Varne, A. A. (2024). Ribose 5 Phosphate I Some Rased Eficiency: A Rare Metabolic Disorder. International Journal of Community Pharmacy, 32-40.

28. Muzammal, M., Fatima, S., Gul, A., Qayum, J., Farid, A., Ahmad, S., ... & Khan, M. A. (2023). Computational analyses of RPIA gene mutation causing Ribose-5-phosphate isomerase deficiency: a rarest known metabolic disorder in humans. Journal of Taibah University for Science, 17(1), 2262753.

29. Naik, N., Shah, A., Wamelink, M. M., van der Knaap, M. S., & Hingwala, D. (2017). Rare case of ribose 5 phosphate isomerase deficiency with slowly progressive leukoencephalopathy. Neurology, 89(11), 1195-1196.

30. Nieh, Y. C., Chou, Y. T., Chou, Y. T., Wang, C. Y., Lin, S. X., Ciou, S. C., ... & Wang, H. D. (2022). Suppression of ribose-5-phosphate isomerase a induces ROS to activate autophagy, apoptosis, and cellular senescence in lung cancer. International Journal of Molecular Sciences, 23(14), 7883.

31. Qiao, J., Yu, Z., Zhou, H., Wang, W., Wu, H., & Ye, J. (2025). The pentose phosphate pathway: from mechanisms to implications for gastrointestinal cancers. International Journal of Molecular Sciences, 26(2), 610.

32. Qiu, Z., Guo, W., Wang, Q., Chen, Z., Huang, S., Zhao, F., ... & He, X. (2015). MicroRNA-124 reduces the pentose phosphate pathway and proliferation by targeting PRPS1 and RPIA mRNAs in human colorectal cancer cells. Gastroenterology, 149(6), 1587-1598.

33. Rashida, Z., & Laxman, S. (2021). The pentose phosphate pathway and organization of metabolic networks enabling growth programs. Current Opinion in Systems Biology, 28, 100390.

34. Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., ... & Lalatsa, A. (2024). Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. Pharmaceutics, 16(10), 1328.

35. Shayota, B. J., Donti, T. R., Xiao, J., Gijavanekar, C., Kennedy, A. D., Hubert, L., ... & Elsea, S. H. (2020). Untargeted metabolomics as an unbiased approach to the diagnosis of inborn errors of metabolism of the non-oxidative branch of the pentose phosphate pathway. Molecular genetics and metabolism, 131(1-2), 147-154.

36. Shen, W. C., Yuh, C. H., Lu, Y. T., Lin, Y. H., Ching, T. T., Wang, C. Y., & Wang, H. D. (2023). Reduced ribose-5-phosphate isomerase A-1 expression in specific neurons and time points promotes longevity in Caenorhabditis elegans. Antioxidants, 12(1), 124.

37. Stincone, A., Prigione, A., Cramer, T., Wamelink, M. M., Campbell, K., Cheung, E., ... & Ralser, M. (2015). The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. Biological Reviews, 90(3), 927-963.

38. Teli, P., Kale, V., & Vaidya, A. (2023). Beyond animal models: revolutionizing neurodegenerative disease modeling using 3D in vitro organoids, microfluidic chips, and bioprinting. Cell and tissue research, 394(1), 75-91.

39. Wamelink, M. M., Valayannopoulos, V., & Garavaglia, B. (2022). Disorders of glycolysis and the pentose phosphate pathway. In Inborn Metabolic Diseases: Diagnosis and Treatment (pp. 209-223). Berlin, Heidelberg: Springer Berlin Heidelberg.

40. Wojtara, M., Rana, E., Rahman, T., Khanna, P., & Singh, H. (2023). Artificial intelligence in rare disease diagnosis and treatment. Clinical and Translational science, 16(11), 2106-2111.